TGFB1 and pulmonary fibrosis: As it is evident in Table 2, BLM and lipopolysaccharides (LPS) are used for induction of pulmonary fibrosis, and in most cases, treatment with different substance reverses this process by inhibiting TGF‐β/SMAD and other inflammatory pathways.